TESARO is devoted to providing transformative therapies to people bravely facing cancer.

Our Corporate History

2017

Rolapitant Oral MAA Receives Positive Opinion from CHMP

Zejula™ (niraparib) Approved by FDA and Launched in the U.S.

2016

$155 Million Private Placement Completed

Rolapitant IV NDA Submitted to U.S. FDA

Rolapitant Oral MAA Submitted to EMA

Phase 1 Trials of TSR-042 and TSR-022 Initiated

Immuno-oncology Collaboration with MD Anderson Announced

Collaboration with Janssen in Prostate Cancer Began

Results of Phase 3 NOVA Trial of Niraparib Announced

$409 Million Follow-on Stock Offering Completed

Phase 3 Trial of Niraparib in 1st Line Ovarian Cancer Initiated (PRIMA)

$236 Million Follow-on Stock Offering Completed

Niraparib NDA Submitted to U.S. FDA

Niraparib MAA Submitted to EMA

2015

$192M Follow-on Stock Offering Completed

Collaboration with Merck Announced to Evaluate Niraparib in Combination with Pembrolizumab

First Product VARUBI® Oral (Rolapitant) Approved by FDA and launched in the U.S.

Rolapitant IV NDA Submitted to U.S. FDA

European Headquarters Opened in Zug, Switzerland

2014

$101M Follow-on Stock Offering Completed

Final Phase 3 Trial of Rolapitant Oral Completed

Niraparib Phase 3 Trial in Breast Cancer Initiated (BRAVO)

Rolapitant Oral NDA Submitted to U.S. FDA

$201M Convertible Debt Offering Completed

2013

$98M Follow-on Stock Offering Completed

First Phase 3 Trial of Niraparib in Ovarian Cancer Initiated (NOVA)

Rolapitant IV Clinical Program Initiated

Top-line Results of First Two Phase 3 Trials of Rolapitant Oral Announced

2012

Three Phase 3 Trials of Rolapitant Oral Initiated

Niraparib In-licensed

Initial Public Offering (NASDAQ: TSRO) Completed

2011

$101M Series B Financing Completed

2010

TESARO Founded

$20M Series A Financing Completed

Rolapitant In-licensed